She arrived at the clinic exhausted, carrying a notebook of symptom logs. For 10 to 14 days before each period, she experienced rage, hopelessness, inability to work, relationship conflict, and thoughts of suicide. Her gynecologist suspected premenstrual dysphoric disorder (PMDD) and discussed an SSRI. This severity is not ordinary menstrual discomfort and should not be managed with herbal tea alone. Ayurveda may offer supervised complementary care, but severe mood symptoms require diagnosis, a safety plan, and coordinated medical and mental care.

PMDD vs PMS: The Critical Distinction

Premenstrual syndrome (PMS) refers to physical, emotional, or behavioral symptoms that recur before menstruation and improve after bleeding begins. Symptoms may include irritability, mood change, breast tenderness, bloating, headache, fatigue, appetite change, and disturbed sleep. PMS can affect daily life; PMDD is distinguished by prominent mood symptoms, marked distress, and substantial interference with work, school, social activity, or relationships.

DSM-5 criteria require at least five symptoms in the final week before menstruation, improving within days after bleeding begins and becoming minimal afterward. At least one must be marked mood swings, irritability or anger, depressed mood or hopelessness, or anxiety and tension. Symptoms must not merely reflect another disorder, substance, medicine, or medical condition.

The pattern should be confirmed with prospective daily ratings during at least two symptomatic cycles, although a provisional diagnosis may be made earlier. Tracking helps distinguish PMDD from premenstrual worsening of another psychiatric or medical condition. Thoughts of self-harm or suicide require urgent assessment regardless of cycle timing.

What Classical Ayurveda Can Legitimately Contribute

Classical Ayurvedic texts do not contain PMDD as a named diagnosis. It is therefore inaccurate to call PMDD simply artava dushti, a disorder of manovaha srotas, or a particular yonivyapad. These are Ayurvedic categories with their own meanings and cannot be declared equivalent to a modern psychiatric diagnosis.

A classical statement that can be made accurately is that apana vata participates in the expulsion of artava. Ashtanga Hridaya, Sutrasthana 12.9, lists the elimination of artava, feces, urine, reproductive fluid, and the fetus among apana’s functions. This supports examining menstruation, pelvic symptoms, and bowel function, but it does not prove that blocked apana causes PMDD or that menstruation is a monthly “detox.”

An Ayurvedic consultation may assess appetite, digestion, bowel habits, sleep, bleeding, pain, constitution, dosha disturbance, stress, diet, and medicine use. This may individualize supportive care, but severe depression, anxiety, or rage must not be reduced to a dosha label. Psychiatric risk takes priority.

A Cautious Dosha-Informed Assessment

This observational Ayurvedic framework is not a validated PMDD diagnostic tool. It shows questions a practitioner may explore while maintaining medical assessment and direct safety screening.

Observed Pattern Ayurvedic Consideration Clinical Caution
Restlessness, racing thoughts, poor sleep, constipation Vata aggravation may be considered Also assess anxiety, sleep loss, medicines, and thyroid disease
Irritability, heat, headache, loose stools, burning Pitta-associated heat or sharpness may be considered Do not explain dangerous anger or loss of control by Pitta alone
Heaviness, oversleeping, withdrawal, low motivation Kapha-associated heaviness may be considered Assess depression, functional decline, and suicidal thinking
Shifts among anxiety, anger, crying, and exhaustion A mixed pattern may be present Avoid a standard online protocol; seek individualized care

Ayurvedic Herbs: Traditional Identity Is Not PMDD Evidence

Shatavari, Ashoka, Brahmi, Shankhapushpi, and Manjistha are genuine Ayurvedic drugs with pharmacopoeial or traditional recognition. The Ayurvedic Pharmacopoeia of India supports standards for identity and quality; inclusion does not prove that a drug treats diagnosed PMDD. PMDD-specific evidence does not justify the fixed luteal-phase doses in the original article.

Shatavari (Asparagus racemosus) is traditionally used in nourishing and reproductive-health contexts. It is not a proven estrogen balancer or established PMDD phytoestrogen. Studies concerning lactation or menopausal symptoms cannot be converted into a PMDD prescription.

Ashoka (Saraca asoca) stem bark is an official Ayurvedic drug associated with gynecological use. This does not prove that it treats PMDD or suicidal thoughts. Laboratory or animal findings cannot support a fixed PMDD dose.

Brahmi requires correct botanical identification: Bacopa monnieri and Centella asiatica are not interchangeable. Bacopa research does not establish correction of PMDD serotonin pathways or a predictable eight-to-twelve-week PMDD response.

Shankhapushpi requires botanical verification because more than one plant is sold under the name. Convolvulus pluricaulis is a recognized source, but no adequate evidence supports a universal PMDD powder or syrup dose.

Manjistha (Rubia cordifolia) is traditionally used in contexts involving rakta and skin disorders. “Blood purifier” is not a demonstrated biomedical mechanism, and evidence does not show that Manjistha treats PMDD rage or inflammation.

Herbs should be selected by a qualified Ayurvedic practitioner who knows the patient’s medicines, pregnancy possibility, allergies, organ health, and psychiatric history. Product substitution and interactions matter. Do not stop an SSRI, hormonal medicine, or psychotherapy to try herbs without the prescriber’s supervision.

A Cycle-Based Plan Without a False 28-Day Formula

A rigid schedule labeling days 1–13 as follicular and days 14–28 as luteal assumes ovulation on day 14 and a 28-day cycle. Cycles and ovulation vary. Planning should be tied to daily symptom records, the person’s usual cycle, and the point at which symptoms predictably begin.

Cycle Stage Goal Practical Actions
Symptom-minimal days Review and prepare Review the diary, refill prescribed medicines, attend appointments, and update the safety plan
Before expected symptoms Reduce avoidable strain Protect sleep, eat regularly, arrange support, and reduce optional high-stress commitments
During the symptom window Maintain treatment and safety Follow the approved plan, avoid alcohol and recreational drugs, and use agreed coping strategies
When symptoms become severe Escalate care Contact a clinician or emergency service for suicidal thoughts, loss of control, or inability to stay safe

Castor oil and Triphala should not be recommended automatically to “move apana downward.” Castor oil is a stimulant laxative that can cause cramping, diarrhea, and dehydration. Triphala can alter bowel function and may not suit every person or medicine schedule. Persistent constipation, diarrhea, pelvic pain, or abnormal bleeding needs assessment rather than routine purgation.

Food, Movement, Sleep, and Psychological Care

Balanced meals and regular timing can prevent hunger or dehydration from adding to fatigue and irritability. Warm meals may suit Ayurvedic preference and individual digestion, but cold or raw foods have not been shown to block apana or cause PMDD. Food triggers should be judged from individual tracking, not universal rules.

Caffeine may worsen anxiety, palpitations, or sleep in sensitive people. Alcohol can worsen sleep, judgment, impulsivity, and mood and is especially unsafe when suicidal thinking is present. Magnesium has been studied for PMS, but evidence does not establish one universal 360 mg luteal-phase regimen for PMDD. Supplements may cause diarrhea, interact with medicines, or be unsuitable in significant kidney disease.

Exercise, yoga, meditation, mindfulness, and stress management are supportive options in professional guidance. They may help within a multimodal plan but cannot replace treatment of severe PMDD. Cognitive behavioral therapy may help coping, relationship strain, and safety planning without implying that PMDD is imaginary.

Shirodhara, Medical Treatment, and Safety

Shirodhara is an Ayurvedic external procedure in which a continuous stream of oil or another prescribed liquid is applied to the forehead. Small studies have explored relaxation, sleep, or physiological responses, but no adequate evidence establishes Shirodhara as a treatment for PMDD, suicidal ideation, or a specific serotonin abnormality.

A professionally administered session may be optional relaxation support after medical assessment. It must not be the main response to suicidal thoughts, severe depression, agitation, psychosis, or inability to stay safe. A trained practitioner should determine suitability and coordinate with the healthcare team.

Evidence-based treatment may include SSRIs, selected hormonal approaches, psychological therapy, exercise, nutritional measures, and specialist care for resistant symptoms. SSRIs may be prescribed continuously or during the luteal phase, depending on the medicine and the individual case. Medication should be started, adjusted, or tapered only with a qualified prescriber.

Safety note: Suicidal thoughts, a suicide plan, recent self-harm, access to lethal means, severe agitation, psychosis, or inability to remain safe require immediate help from local emergency services or the nearest emergency department. Do not leave an actively suicidal person alone. Ayurvedic herbs and procedures are complementary support and must not delay crisis care. Consult a qualified Ayurvedic practitioner and an appropriate healthcare provider before beginning treatment.

Record symptoms every day for at least two cycles, including symptom-minimal days after menstruation. Track mood, irritability, anxiety, concentration, energy, sleep, appetite, physical symptoms, bleeding, functional impairment, medicines, and major stressors. A validated tool such as the Daily Record of Severity of Problems can help distinguish PMDD from PMS and from premenstrual exacerbation of another disorder.

The responsible Ayurvedic approach is not a universal herb list or a promise to clear apana. It is a coordinated plan that recognizes risk, verifies the cyclic pattern, preserves evidence-based treatment, and adds individualized diet, routine, yoga, counseling, or practitioner-prescribed Ayurvedic care only when the likely benefits outweigh the risks.

References

  1. NCBI
  2. Toward the Reliable Diagnosis of DSM-5 Premenstrual Dysphoric Disorder: The Carolina Premenstrual Assessment Scoring System (C-PASS) (2017), PubMed Central
  3. Rcog (rcog.org.uk)
  4. ACOG
  5. Suicidal Risk in Women with Premenstrual Syndrome and Premenstrual Dysphoric Disorder: A Systematic Review and Meta-Analysis (2021), PubMed Central
  6. Easyayurveda (easyayurveda.com)
  7. Ayurvedic Pharmacopoeia of India
  8. Ayurvedic Pharmacopoeia of India
  9. Ayurvedic Pharmacopoeia of India
  10. Ayurvedic Pharmacopoeia of India
  11. An update on Ayurvedic herb Convolvulus pluricaulis Choisy (2014), PubMed Central
  12. Efficacy and Safety of Shatavari Root Extract for the Management of Menopausal Symptoms: A Double-Blind, Multicenter, Randomized Controlled Trial (2024), PubMed
  13. Meta-analysis of randomized controlled trials on cognitive effects of Bacopa monnieri extract (2014), PubMed
  14. NCBI
  15. Shirodhara: A psycho-physiological profile in healthy volunteers (2013), PubMed Central